Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2016

View Archived Issues

Synthetic gene network maintains thyroid hormone homeostasis in experimental Graves' disease

IL-36 as a potential target for intestinal wound healing

AVROBIO to develop cell and gene therapies targeting immune-oncology and rare diseases

Cleveland HeartLab launches blood test for TMAO

Briviact approved in the U.S. for the treatment of partial-onset seizures

Boehringer Ingelheim Pharma discloses new neutrophil elastase inhibitors

Taisho Pharmaceutical patents NHE-3 inhibitors

Innov17 introduces ROR ligands

FDA accepts EOquin NDA for review

PD-1 inhibition improves memory and reduces beta-amyloid plaques in Alzheimer's disease model

The University of Tokyo and Sanofi KK sign strategic partnership agreement

Pfizer describes TrK-A inhibitors

Group in Germany patents PPARgamma antagonists

University of Oklahoma introduces RPE65 proteins

FDA extends Probuphine NDA review date

FDA accepts for review LixiLan NDA

Agilis Biotherapeutics and Waisman Biomanufacturing sign manufacturing agreement for AGIL-FA

AstraZeneca starts first-in-human trial of AZD-5634

New phase Ib study investigates TRC-105 with paclitaxel/carboplatin and bevacizumab for NSCLC

Amgen and UCB report results from phase III FRAME study of romosozumab

Chembio receives grant to develop PoC Zika diagnostics

Bayer's Kovaltry receives E.U. approval for hemophilia A

WHO approves "meran" as suffix for mRNA pharmaceuticals

Flag Therapeutics compound granted FDA orphan status for treating glioma

Serendex receives Japanese approval to start phase II/III trial of Molgradex in PAP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...